R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.
暂无分享,去创建一个
Takuya Matsunaga | Gary Park | Wayne Lang | Matt Duan | V. Markovtsov | C. Low | Y. Hitoshi | D. Payan | T. Matsunaga | C. Liu | J. McLaughlin | Rajinder Singh | K. Shimoda | Elizabeth G Tonkin | Donald G Payan | Polly Pine | G. Park | Marina S. Gelman | W. Lang | Kotaro Shide | Takuro Kameda | Kazuya Shimoda | Yasumichi Hitoshi | Somasekhar Bhamidipati | Chian Liu | Vadim Markovtsov | Andrea Reitsma | Haruko K Shimoda | Elizabeth Tonkin | Shuling Fang | Marina Gelman | Jason Romero | John McLaughlin | Jeffrey Clough | Caroline Low | Stacey Siu | Allan Torneros | Rajinder Singh | P. Pine | T. Kameda | K. Shide | H. Shimoda | Andrea Reitsma | Jason M. Romero | S. Fang | S. Siu | M. Duan | J. Clough | Somasekhar Bhamidipati | Allan Torneros
[1] D. Gilliland,et al. A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. , 2007 .
[2] A. Tefferi,et al. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.
[3] S. Constantinescu,et al. JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation , 2005, Journal of Biological Chemistry.
[4] A. Tefferi. Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.
[5] T. Barbui,et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. , 2004, Haematologica.
[6] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[7] H. Drexler,et al. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders , 2006, Leukemia.
[8] Qingshan Li,et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. , 2007, Blood.
[9] Michael G. Kharas,et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. , 2010, Cancer cell.
[10] R. Levine,et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.
[11] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[12] P. Doherty,et al. Defective Lymphoid Development in Mice Lacking Jak3 , 1995, Science.
[13] Lond Mb. Frederick Ronald Chistopher Casson. , 1975 .
[14] G. Barosi,et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.
[15] Z. Estrov,et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. , 2010, Blood.
[16] References , 1971 .
[17] Sandra A. Moore,et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. , 2008, Cancer cell.
[18] Sandra A. Moore,et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.
[19] J. D. van der Walt,et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. , 2005, The New England journal of medicine.
[20] Stefan N Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.
[21] S. Verstovsek,et al. Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders. , 2007 .
[22] W. Vainchenker,et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.
[23] T. Pearson,et al. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. , 1978, Lancet.
[24] S. Fiering,et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. , 2009, Blood.
[25] A. Dispenzieri,et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. , 2001, Blood.
[26] D. Gilliland,et al. A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden. , 2009 .
[27] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[28] Rudolf Jaenisch,et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor , 1995, Cell.
[29] B. Druker,et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. , 2006, Cancer research.
[30] R. Fanin,et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) , 2008, Haematologica.
[31] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[32] R. Tiedt,et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. , 2007, Blood.
[33] M. Cazzola,et al. A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea. , 2009 .
[34] H. Kantarjian,et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. , 2006, Blood.
[35] Pawel Dobrzanski,et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. , 2008, Blood.
[36] T. Barbui,et al. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia , 2008, Leukemia.
[37] R. Schreiber,et al. Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses , 1998, Cell.
[38] D. Wojchowski,et al. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. , 2006, The Journal of clinical investigation.
[39] K. Takenaka,et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F , 2008, Leukemia.
[40] J. D. Engel,et al. GATA1-related leukaemias , 2008, Nature Reviews Cancer.
[41] D. Gilliland,et al. A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis , 2008 .
[42] T. Pearson,et al. VASCULAR OCCLUSIVE EPISODES AND VENOUS HÆMATOCRIT IN PRIMARY PROLIFERATIVE POLYCYTHÆMLX , 1978, The Lancet.
[43] H. Kantarjian,et al. Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. , 2007 .